Clinical Trial News and Research

RSS

Senhwa Biosciences raises additional $17 million USD in Series B financing

Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today.

12 Dec 2013

Combination therapy safe and active in follicular lymphoma

One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response.

12 Dec 2013

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

Men with hormone-sensitive metastatic prostate cancer who received the chemotherapy drug docetaxel given at the start of standard hormone therapy lived longer than patients who received hormone therapy alone, according to early results from a National Institutes of Health-supported randomized controlled clinical trial.

12 Dec 2013

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

GlaxoSmithKline plc announced today that a peer-reviewed study issued online by the New England Journal of Medicine has reported that GSK's FluLaval® Quadrivalent reduced flu cases among children ages 3-8 by 55.4% overall and lowered the risk of developing moderate-to-serious flu illness by 73.1%.

12 Dec 2013

Queen's University to lead €6 million European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a -6 million European study to find new treatments for bowel cancer.

12 Dec 2013

Tohoku University, Thomson Reuters team up to restore Tohoku’s medical system

The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a collaboration with Tohoku University Tohoku Medical Megabank Organization (ToMMo) to help restore Tohoku's medical system to its pre-earthquake state and help its medical community further develop its research efforts.

12 Dec 2013

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

12 Dec 2013

Avinger closes significant funding round to initiate clinical trial on peripheral atherectomy catheter

Avinger, Inc. producer of therapeutic devices incorporating intravascular imaging and pioneer of the lumivascular approach to treating vascular disease, announced today the closing of a significant funding round.

12 Dec 2013

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers say that a drug approved to treat lung cancer substantially shrank tumors in mice that were caused by a rare form of bone cancer called chordoma.

12 Dec 2013

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

11 Dec 2013

New drug combination therapy effective for patients with HER2-positive breast cancer

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.

11 Dec 2013

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

A team of researchers from Brigham and Women's Hospital, Boston Medical Center and Massachusetts General Hospital has been awarded $25 million by the National Institutes of Health to conduct a four-year, randomized clinical trial-the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia.

11 Dec 2013

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

Absorption Pharmaceuticals LLC in collaboration with Kaiser Permanente announced today the initiation of a clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation. This Phase III, double blind, placebo-controlled, randomized study will measure the intravaginal ejaculatory latency time for subjects aged 18 and older.

11 Dec 2013

Schizophrenia treatment responses follow distinct trajectories

The positive and negative symptoms of schizophrenia generally change in parallel with each other, shows research, supporting the notion that the different symptom domains of the condition have a shared underlying pathology.

11 Dec 2013

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Meniere's disease.

11 Dec 2013

Queen's University heads key European study to find new treatments for bowel cancer

Queen's University has announced it is to lead a €6 million European study to find new treatments for bowel cancer.

11 Dec 2013

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Surefire Medical, Inc. today announced that it has completed enrollment in the Coiling vs. Surefire Infusion System in Y90 (COSY) clinical trial.

11 Dec 2013

Researchers personalizing cancer treatments for young patients

The aim of personalizing cancer treatments by targeting genomic mutations in the cancer has seen rapid advances in recent years. However, many of these targeted cancer therapies have been more frequently identified for adult patients. Recognizing a need to further explore genomic profiling in pediatric malignancies, the Hugs for Brady Foundation has committed $300,000 to the precision medicine initiative at Rutgers Cancer Institute of New Jersey.

11 Dec 2013

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Children with acute lymphoblastic leukemia (ALL), the most common form of pediatric cancer, can safely receive intravenous infusions of a reformulated mainstay of chemotherapy that has been delivered via painful intramuscular injection for more than 40 years, research suggests.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Clinical Trial News and Research

Senhwa Biosciences raises additional $17 million USD in Series B financing

Combination therapy safe and active in follicular lymphoma

Early docetaxel drug with ADT increases survival of men with metastatic prostate cancer

GSK's FluLaval Quadrivalent vaccine effective in reducing flu cases in children

Queen's University to lead €6 million European study to find new treatments for bowel cancer

Tohoku University, Thomson Reuters team up to restore Tohoku’s medical system

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Avinger closes significant funding round to initiate clinical trial on peripheral atherectomy catheter

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Romidepsin drug shows surprising benefit in preclinical studies of inflammatory breast cancer

New drug combination therapy effective for patients with HER2-positive breast cancer

Researchers awarded $25 million NIH grant to study critical limb ischemia treatment

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

Schizophrenia treatment responses follow distinct trajectories

First patient enrolled in Otonomy's pivotal Phase 2b study of OTO-104 for Meniere's disease

Queen's University heads key European study to find new treatments for bowel cancer

Surefire Medical enrolls patients in COSY clinical trial to investigate benefits of SIRT in liver metastasis

Researchers personalizing cancer treatments for young patients

Study shows children with ALL can safely receive intravenous infusions of chemotherapy

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer